Elsalys Biotech Says New Studies Confirm Anti-CD160 Potential in Ophthalmology

July 6, 2018: By Jon Swedien

Two recent studies have confirmed that Elsalys Biotech’s first-in-class anti-CD160 antibody, ELB01101, is a potential therapeutic for neovascular eye diseases, France-based Elsalys reported July 2.

ELB01101 is intended to engage CD160 and induce cell death of endothelial cells that surround newly formed blood vessels, blocking their formation.

The first study showed that CD160 endothelial expression in retinal vessels was significantly higher in patients with neovascular diseases, and it correlates with a wide range of ocular neovascular diseases.

The second study also showed ELB01101, in relevant animal models, demonstrated a therapeutic benefit alone and in combination with anti-VEGF agents. Elsalys said the antiangiogenic effect of the combination treatment was significantly higher than either antibody alone, suggesting that the anti-CD160 may act independently of the VEGF pathway and could be a good alternative for patients that poorly respond to an anti-VEGF treatment.

The studies were published in the Investigative Ophthalmology & Visual Science.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Carl Zeiss Meditec Announces Milestone of 1.5 Million SMILE Procedures

Heidelberg Gains US Clearance for OCT Angiography Module

ASCRS Convenes Task Force to Study CyPass Data, Make Recommendations

Bascom Palmer Treats First US Patient in Nightstar’s Trial for X-Linked Retinitis Pigmentosa

First Patient Treated in Allotex’ Trial for Allogenic Refractive Lenticules for Presbyopia

Bausch + Lomb Announces Positive Results for Loteprednol Etabonate Gel

LumiThera Set to Launch Valeda Light Delivery System for Dry AMD

Kodiak Sciences Names Jason Ehrlich, MD, PhD, Chief Medical Officer

Second Sight Receives $1.6 Million Grant from NIH to Support Orion Program

Regeneron to Invest $800 Million in New York Campus

American Women Raise Funds for Nepal Mission to Reduce Corneal Blindness

Ziemer to Add Lenticule Extraction Capabilities to LDV Z8

Stealth BioTherapeutics Raises $100 Million in Support of Elamipretide for Dry AMD

STAAR Gains US Approval of Visian Toric ICL

Sun Pharma, SPARC Announce FDA Approval for Xelpros for Open-Angle Glaucoma, Ocular Hypertension

FDA Will Review Regeneron’s Submission to Expand Eylea’s Labeling to All DR Patients

Alcon Will Locate Headquarters in Switzerland

Kodiak Sciences Files for $100 Million IPO

Iridex Announces $10 Million Public Offering

Oxford BioMedica Expands Capacity with New Facility

Coming soon

2018 Ophthalmic Deals Book: Venture Funding, Commercial Equity, and Business/Technology Sales